T-Cell Acute Lymphoblastic Leukemia - Pipeline Insight, 2021

Publisher Name :
Date: 12-Oct-2021
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "T-Cell Acute Lymphoblastic Leukemia - Pipeline Insight, 2021," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in T-Cell Acute Lymphoblastic Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

T-Cell Acute Lymphoblastic Leukemia Understanding

T-Cell Acute Lymphoblastic Leukemia: Overview

T-cell acute lymphoblastic leukaemia (T-ALL) is a type of acute leukaemia meaning that it is aggressive and progresses quickly. It affects the lymphoid-cell-producing stem cells, in paticular a type of white blood cell called T lymphocytes as opposed to acute lymphoblastic leukaemia (ALL) which commonly affects B lymphocytes. T-cell acute lymphoblastic leukemia (T-ALL) represents approximately 12% to 15% of all newly diagnosed ALL cases in pediatric patients and is noteworthy for its unique clinical and biological features. There are no specific signs or symptoms which would allow a diagnosis of T-ALL to be made. The most common signs and symptoms are caused by the bone marrow being unable to produce enough normal blood cells. Most T-ALL disease recurrences occur within 2 years of diagnosis, and relapsed disease remains very difficult to salvage, with survival rates lower than 25%. Patients with newly diagnosed T-ALL are typically treated with risk-based multiagent chemotherapy regimens for 2 to 3 years, with or without cranial radiation therapy (CRT).

"T-Cell Acute Lymphoblastic Leukemia - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the T-Cell Acute Lymphoblastic Leukemia pipeline landscape is provided which includes the disease overview and T-Cell Acute Lymphoblastic Leukemia treatment guidelines. The assessment part of the report embraces, in depth T-Cell Acute Lymphoblastic Leukemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, T-Cell Acute Lymphoblastic Leukemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence T-Cell Acute Lymphoblastic Leukemia R&D. The therapies under development are focused on novel approaches to treat/improve T-Cell Acute Lymphoblastic Leukemia.

T-Cell Acute Lymphoblastic Leukemia Emerging Drugs Chapters

This segment of the T-Cell Acute Lymphoblastic Leukemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

T-Cell Acute Lymphoblastic Leukemia Emerging Drugs

- Isatuximab: Sanofi

Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line. Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma. Along with daratumumab, another anti-CD38 mAb, isatuximab constitutes a novel treatment modality for patients with difficult-to-treat multiple myeloma. The drug is currently being evaluated in Phase II stage of development for the treatment of T-cell acute lymphoblastic leukemia.

- CPX-351: Jazz Pharmaceuticals

Liposomal cytarabine-daunorubicin CPX-351 combines two chemotherapy drugs that are known to help each other work better, and may work to stop the growth of cancer cells by blocking the cells from dividing. The notable clinical efficacy of CPX-351 is achieved through maintenance of a synergistic 5:1 molar ratio of cytarabine and daunorubicin within the liposome after intravenous injection. It is being evaluated in Phase II clinical trial to treat T-cell acute lymphoblastic leukemia.

Further product details are provided in the report……..

T-Cell Acute Lymphoblastic Leukemia: Therapeutic Assessment

This segment of the report provides insights about the different T-Cell Acute Lymphoblastic Leukemia drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in T-Cell Acute Lymphoblastic Leukemia

There are approx. 12+ key companies which are developing the therapies for T-Cell Acute Lymphoblastic Leukemia. The companies which have their T-Cell Acute Lymphoblastic Leukemia drug candidates in the most advanced stage, i.e. Phase II include, Sanofi.

- Phases

DelveInsight's report covers around 12+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

T-Cell Acute Lymphoblastic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral

- Parenteral

- Intravenous

- Subcutaneous

- Topical.

- Molecule Type

Products have been categorized under various Molecule types such as

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Gene therapy

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

T-Cell Acute Lymphoblastic Leukemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses T-Cell Acute Lymphoblastic Leukemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging T-Cell Acute Lymphoblastic Leukemia drugs.

T-Cell Acute Lymphoblastic Leukemia Report Insights

- T-Cell Acute Lymphoblastic Leukemia Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

T-Cell Acute Lymphoblastic Leukemia Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing T-Cell Acute Lymphoblastic Leukemia drugs?

- How many T-Cell Acute Lymphoblastic Leukemia drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of T-Cell Acute Lymphoblastic Leukemia?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the T-Cell Acute Lymphoblastic Leukemia therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for T-Cell Acute Lymphoblastic Leukemia and their status?

- What are the key designations that have been granted to the emerging drugs?

T-Cell Acute Lymphoblastic Leukemia - Pipeline Insight, 2021

Table of Contents

Introduction
Executive Summary
T-Cell Acute Lymphoblastic Leukemia: Overview
* Causes
* Mechanism of Action
* Signs and Symptoms
* Diagnosis
* Disease Management
Pipeline Therapeutics
* Comparative Analysis
Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
* Comparative Analysis
Drug Name: Company Name
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
* Comparative Analysis
Isatuximab: Sanofi
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
* Comparative Analysis
CD7 CAR T cells: * iCell Gene Therapeutics
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
* Comparative Analysis
T-Cell Acute Lymphoblastic Leukemia Key Companies
T-Cell Acute Lymphoblastic Leukemia Key Products
T-Cell Acute Lymphoblastic Leukemia- Unmet Needs
T-Cell Acute Lymphoblastic Leukemia- Market Drivers and Barriers
T-Cell Acute Lymphoblastic Leukemia- Future Perspectives and Conclusion
T-Cell Acute Lymphoblastic Leukemia Analyst Views
T-Cell Acute Lymphoblastic Leukemia Key Companies
Appendix

List of Tables

Table 1 Total Products for T-Cell Acute Lymphoblastic Leukemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for T-Cell Acute Lymphoblastic Leukemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • China Ocular Drug Delivery Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 91
    China Ocular Drug Delivery Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Doses) China Ocular Drug Delivery Market Segment Percentages, By Type, 2020 (%) - Ocular Insert - Iontophoresis - Intraocular Implants - In Situ Gel & Punctal Plugs - Others China Ocular Drug Delivery Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Doses) China Ocular Drug Delivery Market Segment Percentages, By Application, 2020 (%)......
  • China Nuclear Medicine/Radiopharmaceutic Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 93
    China Nuclear Medicine/Radiopharmaceutic Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (Kiloton) China Nuclear Medicine/Radiopharmaceutic Market Segment Percentages, By Type, 2020 (%) - Tc-99 - I-123/131 - In-111 - Xe-133 - Th-201 - Ga-67 - Other China Nuclear Medicine/Radiopharmaceutic Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (Kiloton) China Nuclear Medicine/Radiopharmaceutic Market Segment P......
  • China NSAIDs Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 90
    China NSAIDs Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China NSAIDs Market Segment Percentages, By Type, 2020 (%) - Aspirin - Ibuprofen - Naproxen - Nabumetone - Others China NSAIDs Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China NSAIDs Market Segment Percentages, By Application, 2020 (%) - Back Pain Treatment - Osteoarthritis Treatment - Other Disease Treatment......
  • China Non-Tyrosine Kinase Inhibitors Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 107
    China Non-Tyrosine Kinase Inhibitors Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Non-Tyrosine Kinase Inhibitors Market Segment Percentages, By Type, 2020 (%) - mTOR Inhibitors - RAF/MEK Inhibitors - CDK Inhibitors China Non-Tyrosine Kinase Inhibitors Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Non-Tyrosine Kinase Inhibitors Market Segment Percentages, By Application, 2020 (%) - Liver Can......
  • China Nonsteroidal Antiinflammatory Drugs Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 90
    China Nonsteroidal Antiinflammatory Drugs Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Nonsteroidal Antiinflammatory Drugs Market Segment Percentages, By Type, 2020 (%) - Oral Nonsteroidal Antiinflammatory Drugs - Injection Nonsteroidal Antiinflammatory Drugs China Nonsteroidal Antiinflammatory Drugs Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Nonsteroidal Antiinflammatory Drugs Market Segment Percenta......
  • China Non-opioid Pain Patch Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 107
    China Non-opioid Pain Patch Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (M Units) China Non-opioid Pain Patch Market Segment Percentages, By Type, 2020 (%) - Lidocaine Patches - Diclofenac Patches - Indomethacin Patches - Counter-Irritant Patches - Fentanyl Patches - Others China Non-opioid Pain Patch Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (M Units) China Non-opioid Pain Patch Market Segment Perc......
  • China Non Narcotic Analgesics Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 92
    China Non Narcotic Analgesics Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Non Narcotic Analgesics Market Segment Percentages, By Type, 2020 (%) - Non Steroid Antiinflammatory Drug - Steroid Antiinflammatory Drug China Non Narcotic Analgesics Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Non Narcotic Analgesics Market Segment Percentages, By Application, 2020 (%) - Hospital - Medical Center......
  • Global Azelastine Nasal Spray Market Research Report 2021
    Published: 26-Oct-2021        Price: US 2900 Onwards        Pages: 100
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - 0.137MG/SPRAY - 0.2055MG/SPRAY - Other Segment by Application - Hospital - Ret......
  • Global Azelastine Drug Market Research Report 2021
    Published: 26-Oct-2021        Price: US 2900 Onwards        Pages: 114
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Nasal Spray - Eye Drops - Other Segment by Application - Hospital - Retail Pha......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs